4.5 Article

Increased Serum Levels of Nε-(hexanoyl)lysine, A New Marker of Oxidative Stress, in Systemic Sclerosis

Journal

JOURNAL OF RHEUMATOLOGY
Volume 35, Issue 11, Pages 2214-2219

Publisher

J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.080191

Keywords

N-epsilon-(HEXANOYL)LYSINE; SYSTEMIC SCLEROSIS; ANTI-AGALACTOSYL IgG ANTIBODY; RHEUMATOID FACTOR

Categories

Ask authors/readers for more resources

Objective. To determine serum levels of N-epsilon-(hexanoyl)lysine (HEL), a new marker of oxidative stress, and its clinical association in patients with systemic sclerosis (SSc). Methods. Serum HEL levels from 26 patients with limited cutaneous SSc (ISSc), 34 with diffuse cutaneous SSc (dSSc), 20 with systemic lupus erythematosus (SLE), 20 with dermatomyositis (DM), and 40 healthy individuals were examined by enzyme linked immunosorbent assay. Results. Serum HEL levels were elevated in patients with SSc compared with healthy controls (n 40) with similar levels between patients with ISSc and dSSc (p < 0.0001). SSc patients with elevated HEL levels had increased serum levels of anti-agalactosyl IgG antibody, rheumatoid factor (RF), and IgM than those with normal HEL levels (p < 0.05). HEL levels correlated positively with anti-agalactosyl IgG antibody.(p = 0.013, r = 0.408) and RF titer (p = 0.0028, r = 0.426). Conclusion. Our results suggest that oxidative stress may play an important role in immunological abnormalities of SSc, especially in the production of autoantibodies including anti-agalactosyl IgG antibody and RE (First Release Sept 1 2008; J Rheumatol 2008;35:2214-9; doi: 10.3899/jrheum.080191)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Decrease in MAP3Ks expression enhances the cell death caused by hyperthermia

Atsushi Enomoto, Takemichi Fukasawa, Hiroshi Terunuma, Keiichi Nakagawa, Ayumi Yoshizaki, Shinichi Sato, Kiyoshi Miyagawa

Summary: This study reveals that hyperthermia can inhibit cell proliferation and clonogenicity by regulating the expression levels of TAK1, RAF1, and MEKK2 in the MAPK signaling pathway. These findings provide potential molecular targets for hyperthermia.

INTERNATIONAL JOURNAL OF HYPERTHERMIA (2022)

Article Dermatology

Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease

Satoshi Ebata, Ayumi Yoshizaki, Takemichi Fukasawa, Asako Yoshizaki-Ogawa, Yoshihide Asano, Kosuke Kashiwabara, Koji Oba, Shinichi Sato

Summary: This study investigated whether B-cell responsiveness to rituximab is related to therapeutic effect in patients with systemic sclerosis-associated interstitial lung disease. The findings suggest that the rate of B-cell clearance after 2 weeks of treatment with rituximab may serve as a useful marker for subsequent improvement in SSc-ILD. Patients with less than 5% residual B cells at week 2 showed significant improvement in lung function compared to baseline.

JOURNAL OF DERMATOLOGY (2022)

Article Rheumatology

Tocilizumab-induced organizing pneumonia in a patient with systemic sclerosis-associated interstitial lung disease

Ai Kuzumi, Shunki Mitsuo, Tomomi Miyake, Shinichi Sato, Ayumi Yoshizaki

RHEUMATOLOGY (2023)

Review Immunology

Involvement of B cells in the development of systemic sclerosis

Ayumi Yoshizaki, Takemichi Fukasawa, Satoshi Ebata, Asako Yoshizaki-Ogawa, Shinichi Sato

Summary: This article outlines the role of B cells in the development of systemic sclerosis (SSc), including their involvement in autoimmune abnormalities, pro-inflammatory actions, and inhibitory functions. Studies have found B-cell depletion therapy to be effective for SSc.

FRONTIERS IN IMMUNOLOGY (2022)

Review Medicine, General & Internal

New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics

Satoshi Ebata, Asako Yoshizaki-Ogawa, Shinichi Sato, Ayumi Yoshizaki

Summary: This paper outlines the latest advances in the treatment of systemic sclerosis (SSc), with a focus on the efficacy and safety of Nintedanib, Tocilizumab, and Rituximab.

JOURNAL OF CLINICAL MEDICINE (2022)

Article Rheumatology

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial

Satoshi Ebata, Ayumi Yoshizaki, Koji Oba, Kosuke Kashiwabara, Keiko Ueda, Yukari Uemura, Takeyuki Watadani, Takemichi Fukasawa, Shunsuke Miura, Asako Yoshizaki-Ogawa, Naoko Okiyama, Masanari Kodera, Minoru Hasegawa, Shinichi Sato

Summary: Rituximab is a safe and effective treatment option for improving skin thickening in patients with systemic sclerosis, with sustained benefits for at least 48 weeks.

LANCET RHEUMATOLOGY (2022)

Article Biochemistry & Molecular Biology

Increased Serum Levels of Tumor Necrosis Factor-like Ligand 1A in Atopic Dermatitis

Teruyoshi Hisamoto, Hiraku Suga, Asako Yoshizaki-Ogawa, Shinichi Sato, Ayumi Yoshizaki

Summary: Atopic dermatitis is a common chronic skin disease characterized by Th2 inflammation. The cytokine TL1A has been found to play a role in chronic inflammatory diseases, but its role in atopic dermatitis is unclear.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Immunology

Significance of anti-transcobalamin receptor antibodies in cutaneous arteritis revealed by proteome-wide autoantibody screening

Kazuki M. Matsuda, Hirohito Kotani, Kei Yamaguchi, Taishi Okumura, Eriko Fukuda, Masanori Kono, Teruyoshi Hisamoto, Ruriko Kawanabe, Yuta Norimatsu, Ai Kuzumi, Maiko Fukayama, Takemichi Fukasawa, Satoshi Ebata, Asako Yoshizaki-Ogawa, Tomohisa Okamura, Hirofumi Shoda, Keishi Fujio, Naoki Goshima, Shinichi Sato, Ayumi Yoshizaki

Summary: Cutaneous arteritis (CA) is a skin vasculitis that affects small to medium-sized arteries. The diagnosis relies on skin biopsy, which can be burdensome. The pathogenesis and treatment of CA are still unclear. In this study, anti-transcobalamin receptor (TCblR) antibodies were found in 24% of CA patients and were associated with skin-limited CA. These antibodies trigger interleukin-6 autocrine loop and induce periarterial inflammation. Methylcobalamin, a ligand of TCblR, can ameliorate inflammation caused by these antibodies. These findings suggest that anti-TCblR antibodies could be a diagnostic marker and a therapeutic target for CA.

JOURNAL OF AUTOIMMUNITY (2023)

Article Rheumatology

Utility of nailfold capillary assessment for predicting psoriatic arthritis based on a prospective observational cohort study

Takemichi Fukasawa, Satoshi Toyama, Atsushi Enomoto, Asako Yoshizaki-Ogawa, Yuta Norimatsu, Shoko Tateishi, Hiroko Kanda, Kiyoshi Miyagawa, Shinichi Sato, Ayumi Yoshizaki

Summary: This study found that nailfold capillary abnormalities in patients with psoriasis may be a predictive factor for the development of psoriatic arthritis (PsA), and the degree of abnormality may be indicative of disease severity.

RHEUMATOLOGY (2023)

Letter Rheumatology

Impact of guselkumab on three cases of SSc accompanying psoriasis

Takemichi Fukasawa, Asako Yoshizaki-Ogawa, Ayumi Yoshizaki, Shinichi Sato

RHEUMATOLOGY (2023)

Article Rheumatology

Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration

Kazuki M. Matsuda, Ayumi Yoshizaki, Ai Kuzumi, Satoshi Toyama, Kentaro Awaji, Tomomi Miyake, Shinichi Sato

Summary: This study aims to summarize the current knowledge on the efficacy of IVIG against GI symptoms of SSc and identify future research directions. The results indicate that IVIG administration can lead to remarkable improvement in GI symptoms, including IPO, and previous reports also support its efficacy. However, further studies with objective and quantitative measures are needed to evaluate short-term outcomes.

RHEUMATOLOGY (2023)

Article Dermatology

Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis Follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels

Ai Kuzumi, Satoshi Ebata, Takemichi Fukasawa, Kazuki M. Matsuda, Hirohito Kotani, Asako Yoshizaki-Ogawa, Shinichi Sato, Ayumi Yoshizaki

Summary: This cohort study found that long-term use of rituximab for systemic sclerosis improved skin and lung fibrosis, and a decrease in serum immunoglobulins was associated with better clinical response.

JAMA DERMATOLOGY (2023)

Article Medicine, General & Internal

Clinical Risk Factors for Dysphagia and Esophageal Dysmotility in Systemic Sclerosis

Mariko Hara, Rumi Ueha, Taku Sato, Takao Goto, Ayumi Yoshizaki, Hayakazu Sumida, Shinichi Sato, Tatsuya Yamasoba

Summary: Systemic sclerosis is often associated with dysphagia and esophageal dysmotility. This study evaluated the association between dysphagia and esophageal dysmotility in patients with systemic sclerosis and identified risk factors. The results showed that dysphagia was associated with autoantibody positivity and older age, while there were no identified risk factors for esophageal dysmotility. No correlation was found between dysphagia and esophageal dysmotility.

JOURNAL OF CLINICAL MEDICINE (2023)

Review Oncology

The Role of Mammalian STK38 in DNA Damage Response and Targeting for Radio-Sensitization

Takemichi Fukasawa, Atsushi Enomoto, Asako Yoshizaki-Ogawa, Shinichi Sato, Kiyoshi Miyagawa, Ayumi Yoshizaki

Summary: DNA is constantly damaged, and cells have evolved DNA damage response mechanisms to preserve genomic integrity. Kinases play a central role in this response by transmitting the DNA damage signal to various cellular processes. Recently, the role of STK38 in DNA damage signaling has emerged.

CANCERS (2023)

Article Medicine, General & Internal

The Autoantibody Array Assay: A Novel Autoantibody Detection Method

Yuta Norimatsu, Kazuki Mitsuru Matsuda, Kei Yamaguchi, Chihiro Ono, Taishi Okumura, Emi Kogo, Hirohito Kotani, Teruyoshi Hisamoto, Ai Kuzumi, Takemichi Fukasawa, Asako Yoshizaki-Ogawa, Naoki Goshima, Shinichi Sato, Ayumi Yoshizaki

Summary: This study developed a new method for detecting SSc and DM autoantibodies (A-cube) and examined its validity. The A-cube method showed comparable or higher sensitivity and specificity compared to existing testing methods, and could potentially lead to re-consideration of diagnosis in certain cases. The quality of the A-cube was ensured, and its usefulness for comprehensive analysis was demonstrated.

DIAGNOSTICS (2023)

No Data Available